Mostrando 10 resultados de: 12
Filtros aplicados
Área de conocimiento
Cáncer(10)
Bioquímica(3)
Descubrimiento de fármacos(2)
Farmacología(2)
Medicamento(1)
Origen
scopus(12)
Androstenedione is the preferred androgen source in hormone refractory prostate cancer Letter
OtherAbstract:Palabras claves:Autores:Richard J. Auchus, Sharifi N.Fuentes:scopus"Getting from here to there"-mechanisms and limitations to the activation of the androgen receptor in castration-resistant prostate cancer
ReviewAbstract: Despite the clinical regression that typifies the initial response of advanced prostate cancer to goPalabras claves:androgen receptor, Androgens, Steroid metabolismAutores:McPhaul M., Richard J. Auchus, Sharifi N.Fuentes:scopus3β-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer
ArticleAbstract: Prostate cancer usually responds to androgen deprivation therapy, although the response in metastatiPalabras claves:Autores:Evaul K., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N.Fuentes:scopusConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusAbiraterone inhibits 3β-hydroxysteroid dehydrogenase: A rationale for increasing drug exposure in castration-resistant prostate cancer
ArticleAbstract: Purpose: Treatment with abiraterone (abi) acetate prolongs survival in castration-resistant prostatePalabras claves:Autores:Chang K.H., Evaul K., Li R., Liu J., Richard J. Auchus, Sharifi N., Sharma K.K., Yoshimoto J.A.Fuentes:scopusDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer
ArticleAbstract: In the majority of cases, advanced prostate cancer responds initially to androgen deprivation therapPalabras claves:5-alpha-androstanedione, Abiraterone acetate, Hormonal therapy, Hormone resistance, Tumor metabolismAutores:Chang K.H., Li R., Papari-Zareei M., Richard J. Auchus, Sharifi N., Watumull L., Zhao Y.Fuentes:scopusMolecular pathways: Inhibiting steroid biosynthesis in prostate cancer
ReviewAbstract: A significant proportion of castration-resistant prostate cancers (CRPC) remains driven by ligand acPalabras claves:Autores:Attard G., Ferraldeschi R., Richard J. Auchus, Sharifi N.Fuentes:scopusHSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer
ArticleAbstract: BACKGROUND. A common germline variant in HSD3B1(1245A>C) encodes for a hyperactive 3β-hydroxysteroidPalabras claves:Autores:Almassi N., Alyamani M., Berk M.P., Chien C., Emamekhoo H., Figg W.D., Garcia J., Grivas P.D., Hu B., Hwang T.H., Koshkin V.S., Mendiratta P., Park S., Peer C.J., Richard J. Auchus, Rini B., Sharifi N., Taylor J., Tyler A., Upadhyay S.K.Fuentes:scopusSex Hormones and Prostate Cancer
ReviewAbstract: The prostate is an androgen-dependent organ that develops only in male mammals. Prostate cancer is tPalabras claves:prostate cancer, androgen, steroidogenesis, abiraterone acetate, adrenalAutores:Richard J. Auchus, Sharifi N.Fuentes:scopusXA gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer
ArticleAbstract: Growth of prostate cancer cells is dependent upon androgen stimulation of the androgen receptor (AR)Palabras claves:Autores:Chang K.H., Guo X., Kapur P., Kuri B., Li R., Liu J., Lotan Y., Mirzaei H., Nelson P.S., Richard J. Auchus, Roehrborn C.G., Sharifi N., Vessella R.Fuentes:scopus